Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences informed exchanges that its subsidiary German Remedies Pharmaceuticals Private Limited (GRPPL) had a Rs. 1.66 million penalty completely dropped by the Office of Commissioner, Central GST, Appeal Ahmedabad Commissionerate. The original penalty was imposed for the financial year 2018-19 concerning alleged excess availment of Input Tax Credit under Section 74 of the CGST Act, 2017. GRPPL had filed an appeal against the Order-In-Original and received the favourable Appeal Order dated April 1, 2026. The company clarified there is no material financial, operational, or other impact on GRPPL or the Company.
This is a positive regulatory development — a penalty has been fully reversed after appeal. The financial quantum is small (Rs. 1.66 million) relative to the company's scale, so the stock impact is likely neutral to marginally positive.